Omalizumab IgE ELISA Assay
The Omalizumab IgE ELISA Assay is For Research Use Only
Size: 1×96 wells
Sensitivity: 1 IU/ml
Dynamic Range:1 – 2000 IU/ml (no Omalizumab in samples), 1-500 IU/ml (Omalizumab present). Omalizumab concentrations can be determined between 0.4-80 µg/ml
Incubation Time: Overnight
Sample Type: Serum
Sample Size: 30 µL
Alternative Names: Omalizumab Free IgE ELISA, Xolair
*Concentration of IgE is calibrated against WHO Reference Reagent, NIBSC Code: 75/ 502
** 1 IU corresponds to 2.4 ng IgE
Allergic asthma is a widespread illness that is initiated or aggravated by allergy-causing substances (allergens). Type E immunoglobulins (IgE) are formed in the organism as a reaction to the allergens, which set in motion the distribution of allergically acting transmitters such as histamine, leukotrines and bradykinins from the mast cells. In the immediate type I reaction, inhalation of the allergen leads directly to constriction of the airways.
In particularly severe cases of allergic bronchial asthma, where the therapeutic antibody Omalizumab (recombinant humanised antibody against IgE) is used, the IgE responsible for triggering the allergic reaction is neutralised by binding. Omalizumab acts as an anti-antibody that prevents the cascade allergic reactions and reduces the binding of IgE to the mast cells. The therapeutic goal of Omalizumab is the reduction of IgE levels in the organism.
The recoveryELISA Omalizumab Free IgE ELISA Assay Kit makes simultaneously determining the free IgE and the available therapeutic antibody possible where Omalizumab is used (Research Use Only).